Citations

Clear

7551 citation(s) found for "Ho, Matthew".

[18F]AV‐1451 tau positron emission tomography in progressive supranuclear palsy
Whitwell, Jennifer L. , Lowe, Val J. , Tosakulwong, Nirubol , Weigand, Stephen D. , Senjem, Matthew L. , Schwarz, Christopher G. , Spychalla, Anthony J., Petersen, Ronald C. , Jack, Clifford R. , Josephs, Keith A. , Jack, Clifford R , Schwarz, Christopher G , Senjem, Matthew L

Mayo Clinic

Movement Disorders | October 27, 2016 | Volume: 32 | Issue: 1 | Pages: 124-133

10.1002/mds.26834 | PMID 27787958 Get It

ABSTRACTBackgroundThe [18F]AV‐1451 positron emission tomography ligand allows the in vivo assessment of tau proteins in the brain. It shows strong binding in Alzheimer's dementia, but little is known about how it performs in progressive supranuclear palsy, a primary 4R tauopathy.ObjectivesThe objectives of this study were to determine whether [18F]AV‐1451 uptake can be observed in progressive supranuclear palsy and to characterize the regional distribution when compared with controls and Alzheimer's dementia.Methods[18F]AV‐1451 positron emission tomography was performed in 10 patients with probable progressive supranuclear palsy. These patients were age‐ and gender‐matched to 50 controls and 10 Alzheimer's dementia patients who had undergone identical [18F]AV‐1451 imaging. Regional comparisons of [18F]AV‐1451 uptake were performed across the whole brain using region‐of‐interest and voxel‐level analyses, and correlations between regional [18F]AV‐1451 and the progressive supranuclear palsy rating scale were assessed.ResultsAn elevated [18F]AV‐1451 signal was observed in progressive supranuclear palsy when compared with controls in the pallidum, midbrain, dentate nucleus of the cerebellum, thalamus, caudate nucleus, and frontal regions. Signal in the cerebellar dentate and pallidum were also greater in progressive supranuclear palsy when compared with Alzheimer's dementia. Conversely, the [18F]AV‐1451 signal across the cortex was higher in Alzheimer's dementia when compared with progressive supranuclear palsy. The [18F]AV‐1451 signal in a number of regions correlated with the progressive supranuclear palsy rating scale.ConclusionsProgressive supranuclear palsy is associated with an elevated [18F]AV‐1451 signal in a characteristic and distinct regional pattern that correlates with disease severity and differs from the patterns observed in Alzheimer's dementia. © 2016 International Parkinson and Movement Disorder Society.
Safety Studies for Use of Adipose Tissue-Derived Mesenchymal Stromal/Stem Cells in a Rabbit Model for Osteoarthritis to Support a Phase I Clinical Trial
Riester, Scott M. , Denbeigh, Janet M. , Yang, Lin , Jones, Dakota L. , Mooij, Tristan de, Lewallen, Eric A. , Nie, Hai , Paradise, Christopher R. , Radel, Darcie J., Dudakovic, Amel , Camilleri, Emily T. , Qu, Wenchun , Krych, Aaron J. , Frick, Matthew A., Im, Hee‐Jeong , Dietz, Allan B. , Smith, Jay , Wijnen, André J. van , Camilleri, Emily , Lin, Yang , de Mooij, Tristan, Larson, Dirk R. , van Wijnen, Andre J, van Wijnen, Andre J , Krych, Aaron J , Dietz, Allan B , van Wijnen, Andre J , Camilleri, Emily

Mayo Clinic

Stem Cells Translational Medicine | October 27, 2016 | Volume: 6 | Issue: 3 | Pages: 910-922

10.5966/sctm.2016-0097 | PMID 28297568 Get It

AbstractAdipose-derived mesenchymal stem cells (AMSCs) offer potential as a therapeutic option for clinical applications in musculoskeletal regenerative medicine because of their immunomodulatory functions and capacity for trilineage differentiation. In preparation for a phase I clinical trial using AMSCs to treat patients with osteoarthritis, we carried out preclinical studies to assess the safety of human AMSCs within the intra-articular joint space. Culture-expanded human AMSCs grown in human platelet-lysate were delivered via intra-articular injections into normal healthy rabbit knees and knees at risk for the development of osteoarthritis after bilateral medial anterior hemimeniscectomy. Treatment outcomes and safety were evaluated by assessing the general health, function, and behavior of the animals. Joint tissues were analyzed by x-ray, magnetic resonance imaging, and histopathology. Intra-articular AMSC therapy was well tolerated in this study. We did not observe adverse systemic reactions, nor did we find evidence of damage to intra-articular joint tissues. Thus, the data generated in this study show a favorable safety profile for AMSCs within the joint space in support of a phase I clinical trial evaluating the clinical utility of AMSCs to treat osteoarthritis.
Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study
Neal‐Perry, Genevieve , Pal, Lubna , Løbo, Rogerio A. , Black, Dennis M. , Budoff, Matthew J. , Cedars, Marcelle I. , Dowling, N. Maritza , Dunn, Mary Hunzicker, Gleason, Carey E. , Hodis, Howard N., Isaac, Barbara, Magnani, Maureen, Miller, Virginia M. , Taylor, Hugh S. , Wharton, Whitney , Wolff, E.F., Zepeda, Viola, Harman, S. Mitchell , Santoro, Nanette, Santoro, Nanette F. , Allshouse, Amanda A. , Naftolin, Frederick , Brinton, Eliot A. , Manson, JoAnn E. , Budoff, Matthew

Mayo Clinic

Menopause | October 25, 2016 | Volume: 24 | Issue: 3 | Pages: 238-246

10.1097/gme.0000000000000756 | PMID 27779568 Get It

Abstract Objective: The objective of the present study was to compare the efficacy of two forms of menopausal hormone therapy in alleviating vasomotor symptoms, insomnia, and irritability in early postmenopausal women during 4 years. Methods: A total of 727 women, aged 42 to 58, within 3 years of their final menstrual period, were randomized to receive oral conjugated estrogens (o-CEE) 0.45 mg (n = 230) or transdermal estradiol (t-E 2 ) 50 μg (n = 225; both with micronized progesterone 200 mg for 12 d each mo), or placebos (PBOs; n = 275). Menopausal symptoms were recorded at screening and at 6, 12, 24, 36, and 48 months postrandomization. Differences in proportions of women with symptoms at baseline and at each follow-up time point were compared by treatment arm using exact χ 2 tests in an intent-to-treat analysis. Differences in treatment effect by race/ethnicity and body mass index were tested using generalized linear mixed effects modeling. Results: Moderate to severe hot flashes (from 44% at baseline to 28.3% for PBO, 7.4% for t-E 2 , and 4.2% for o-CEE) and night sweats (from 35% at baseline to 19% for PBO, 5.3% for t-E 2 , and 4.7% for o-CEE) were reduced significantly by 6 months in women randomized to either active hormone compared with PBO ( P < 0.001 for both symptoms), with no significant differences between the active treatment arms. Insomnia and irritability decreased from baseline to 6 months postrandomization in all groups. There was an intermittent reduction in insomnia in both active treatment arms versus PBO, with o-CEE being more effective than PBO at 36 and 48 months ( P = 0.002 and 0.05) and t-E 2 being more effective than PBO at 48 months ( P = 0.004). Neither hormone treatment significantly affected irritability compared with PBO. Symptom relief for active treatment versus PBO was not significantly modified by body mass index or race/ethnicity. Conclusions: Recently postmenopausal women had similar and substantial reductions in hot flashes and night sweats with lower-than-conventional doses of oral or transdermal estrogen. These reductions were sustained during 4 years. Insomnia was intermittently reduced compared with PBO for both hormone regimens.
A Survey of Perceptions and Acceptance of Wearable Technology for Health Monitoring in a Urological Patient Population
Nehra, Avinash , Gettman, Matthew T., Rivera, Marcelino , Agarwal, Deepak , O’Neil, Daniel A. , Jenkins, Sarah M. , Tollefson, Matthew K. , Viers, Boyd R. , Nehra, Avinash K, Rivera, Marcelino E, Agarwal, Deepak K, Viers, Boyd R

Mayo Clinic

Urology Practice | October 24, 2016 | Volume: 4 | Issue: 6 | Pages: 508-514

10.1016/j.urpr.2016.10.002 | PMID 37300143 Get It

Ultrasonic method to characterize shear wave propagation in micellar fluids
Amador, Carolina , Otilio, Bruno L., Kinnick, Randall R., Urban, Matthew W.

Mayo Clinic

The Journal of the Acoustical Society of America | October 21, 2016 | Volume: 140 | Issue: 3 | Pages: 1719-1726

10.1121/1.4962531 | PMID 27914388 Get It

Viscoelastic micellar fluid characteristics have been measured with mechanically generated shear waves and showed good agreement to shear oscillatory methods. In this paper, shear waves in wormlike micellar fluids using ultrasound were successfully generated and detected. Micellar fluids of different concentrations (100, 200, 300, and 400 mM) were studied with ultrasound-based and conventional rheology methods. The measured micellar fluid complex modulus from oscillatory shear tests between 0.001 and 15.91 Hz was characterized with an extended Maxwell fluid model. The elastic and viscous parameters found using rheological testing were used to estimate shear wave phase velocity over a frequency range from 100 to 500 Hz, and compared to shear wave velocity measured with ultrasound-based methods with a mean absolute error 0.02 m/s. The shear wave frequency content was studied and an increase in shear wave center frequency was found as a function of micellar fluid concentration. Moreover, the bias found in the shear wave group velocity with respect to rheological measurement is attributed to the micellar fluid viscous component. Finally, the shear wave phase velocity evaluated at the center frequency agreed well with the rheological measurements.
P3‐255: PET TAU Imaging with AV‐1451 in Microtubule‐Associated Protein TAU (MAPT) Mutation Carriers Relative to Alzheimer’S Disease Dementia and Controls
Lowe, Val J. , Wiste, Heather J. , Dheel, Christina, Wszolek, Zbigniew, Rademakers, Rosa , Petersen, Ronald C. , Boeve, Bradley F. , Jones, David T. , Senjem, Matthew L. , Kantarci, Kejal , Knopman, David S. , Wszołek, Zbigniew K. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_19 | Pages: No page available

10.1016/j.jalz.2016.06.1918 Get It

IC‐P‐188: AV‐1451 TAU‐PET In Clinical Variants of Progressive Supranuclear Palsy
Josephs, Keith A. , Whitwell, Jennifer L. , Tosakulwong, Nirubol , Weigand, Stephen D. , Petersen, Ronald C. , Lowe, Val J. , Whitwell, Jennifer L. , Senjem, Matthew L. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_3 | Pages: No page available

10.1016/j.jalz.2016.06.219 Get It

P2‐248: Neuropsychological and MRI Findings in MAPT Mutation Carriers in the Evolution from the Asymptomatic to Symptomatic State
Dheel, Christina, Przybelski, Scott A. , Fields, Julie A. , Rademakers, Rosa , Petersen, Ronald C. , Senjem, Matthew L. , Kantarci, Kejal , Jones, David T. , Machulda, Mary M. , Jack, Clifford R. , Knopman, David S. , Wszołek, Zbigniew K. , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_14 | Pages: No page available

10.1016/j.jalz.2016.06.1416 Get It

P1‐247: Network‐Based TAU Deposition Patterns are Related to Functional Network Failure Largely Via Beta‐Amyloid Across the Alzheimer’s Spectrum
Lowe, Val J. , Wiste, Heather J. , Radford, Jonathan Graff, Petersen, Ronald C. , Jones, David T. , Senjem, Matthew L. , Boeve, Bradley F. , Knopman, David S. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_10 | Pages: No page available

10.1016/j.jalz.2016.06.996 Get It

IC‐P‐203: AV‐1451 TAU‐PET Binding in Typical and Atypical Syndromic Variants of Alzheimer’s Disease
Whitwell, Jennifer L. , Josephs, Keith A. , Tosakulwong, Nirubol , Weigand, Stephen D. , Petersen, Ronald C. , Lowe, Val J. , Whitwell, Jennifer L. , Senjem, Matthew L. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_3 | Pages: No page available

10.1016/j.jalz.2016.06.235 Get It